title: [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
abstract: Our objective was to evaluate the efficacy and toxicity of the pre-administration of UFT (uracil/tegafur: prodrug of 5-FU) and GEM combination therapy for unresectable/recurrent pancreatic cancer in the outpatient setting. UFT (250mg/m(2)/day) was orally administered from day 1 through day 6 and from day 8 through 13, and GEM (800mg/m(2), div/30 min) was administered on day 7 and 14, with a one-week rest every 3 weeks based on results of the previous phase I study. Thirty-six pts (24 male, 12 female) were enrolled (median age, 63.8 yrs). There were 8 partial responses (25%). Eighteen pts (56%) had stable disease, and 6 pts (19%) had a progression. The median survival time was 7. 0 months( range 1.5 -66). Grade 3 toxicities were leucopenia (17%), thrombocytopenia (3%), nausea (3%), and liver dysfunctions(3%). There were no Grade 4 toxicities. Pre-administered UFT plus GM is a promising treatment for unresectable/recurrent pancreatic cancer in the outpatient setting.
authors.affiliation: Pancreatic Cancer Study Group, Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University.
authors.forename: Shoji
authors.initials: S
authors.lastname: Nakamori
authors.forename: Wakio
authors.initials: W
authors.lastname: Endo
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ozato
authors.forename: Takashi
authors.initials: T
authors.lastname: Shibata
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Ken
authors.initials: K
authors.lastname: Tohno
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Hasuike
authors.forename: Seizo
authors.initials: S
authors.lastname: Masutani
authors.forename: Takashi
authors.initials: T
authors.lastname: Morimoto
authors.forename: Yuichirou
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D005641:Tegafur; D014498:Uracil; D000093542:Gemcitabine